Ibsrela

Chemical Nametenapanor
Dosage FormTablet (oral; 50 mg)
Drug ClassInhibitors
SystemDigestive
CompanyArdelyx
Approval Year2019

Indication

  • Ibsrela is indicated for treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
Last updated on 11/10/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Ibsrela (tenapanor) Prescribing Information 2019Ardelyx